Drugs.com - Clinical Trials

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

CRANBURY, N.J.--(BUSINESS WIRE)--May 27, 2025-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update...

May 30, 2025 - 05:30
 0
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--May 27, 2025-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update...
Read More

Tags:

Previous Article

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST - Modif...

Next Article

EV Batteries Are Outlasting the Car

Related Posts

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer’s Sasanlimab Combination Significantly Improves ...

May 12, 2025  0

Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD

Sebela Pharmaceuticals Announces Positive Topline Resul...

May 18, 2025  0

Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) in Complete SURMOUNT-5 Results Published in The New England Journal of Medicine

Zepbound (tirzepatide) Showed Superior Weight Loss Over...

May 12, 2025  0